Terms ending in 2033
Every in-force patent on CSL Behring GmbH's record whose computed term ends in 2033, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,474,851 | Holder for an Injection Syringe In force · High confidence | CSL Behring GmbH | In force | High confidence | |
| US 9,957,329 | Factor XII Inhibitors for the Treatment of Neurological Inflammatory Disorders CSL Behring GmbH, CSL Ltd., Julius-Maximilians-Universitaet-Wuerzburg and Westfaelische Wilhelms-Universitaet Muenster In force · High confidence | CSL Behring GmbH, CSL Ltd., Julius-Maximilians-Universitaet-Wuerzburg and Westfaelische Wilhelms-Universitaet Muenster | In force | High confidence | |
| US 9,458,223 | Von Willebrand Factor Variants Having Improved Factor VIII Binding Affinity In force · High confidence | CSL Behring GmbH | In force | High confidence | |
| US 9,932,392 | Prevention of Infection In force · High confidence | CSL Behring AG and Beth Israel Deaconess Medical Center Inc. | In force | High confidence | |
| US 10,188,965 | Hydrophobic Charge Induction Chromatographic Depletion of a Protein from a Solution In force · High confidence | CSL Behring GmbH | In force | High confidence | |
| US 11,426,680 | Hydrophobic Charge Induction Chromatographic Protein Depleted Solution In force · High confidence | CSL Behring GmbH | In force | High confidence | |
| US 9,707,269 | Sugar Compositions for Treating Hemophilia A and/or Von Willebrand Disease In force · High confidence | CSL Behring GmbH | In force | High confidence | |
| US 10,232,015 | Sugar Compositions for Treating Hemophilia A and/or Von Willebrand Disease In force · High confidence | CSL Behring GmbH | In force | High confidence | |
| US 9,937,229 | Methods of Treatment Using Hemopexin Compositions In force · High confidence | CSL Behring AG | In force | High confidence | |
| US 9,518,127 | Inhibitory Anti-Factor XII/Xiia Monoclonal Antibodies and Their Uses In force · High confidence | CSL Ltd. | In force | High confidence | |
| 4 more term ends in 2033 · Pro | |||||
10 of 14 patents shown. Soonest term end first, then patent number.
Pro members see all 14.
12 of these are in force and held by CSL Behring GmbH.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.